GlassScriptPhysician profile
Jee-Hong Kim
NPI 1629423140
$130,768.31
in general payments reported to CMS, 2019-2025
19 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2022: $768 · 2023: $4,866 · 2024: $46K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $13K · Consulting Fee: $9,750 · Food and Beverage: $9,197 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,088.00 |
| Travel and Lodging | $12,721.00 |
| Consulting Fee | $9,750.00 |
| Food and Beverage | $9,196.57 |
| Education | $121.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $79,176.92 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $31,957.65 | 2023-2025 | Nucala |
| Genzyme Corporation | $10,377.89 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $3,214.97 | 2023-2024 | Dupixent |
| Inspire Medical Systems, INC. | $1,567.02 | 2024-2025 | Inspire |
| Medtronic, INC. | $1,127.38 | 2023-2025 | Stealthstation S8 Platform, Fusion, Pteye Parathyroid Detection System |
| Aerin Medical INC. | $1,069.70 | 2025 | |
| Optinose US, INC. | $667.80 | 2022-2025 | |
| Stryker Corporation | $602.59 | 2022-2025 | Scopis Ent |
| Smith+Nephew, INC. | $521.77 | 2025 | Halo |
| Olympus America INC. | $127.04 | 2023 | Rhino-Laryngo Videoscope |
| United Therapeutics Corporation | $81.00 | 2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $63.59 | 2025 | Tezspire |
| Amgen INC. | $56.39 | 2025 | Tezspire |
| Lilly USA, LLC | $55.13 | 2025 | Zepbound, Mounjaro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $37.64 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $22.77 | 2024 | Zerbaxa |
| Karl Storz Endoscopy-America | $21.41 | 2025 | |
| Philips North America LLC | $19.65 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jee-Hong Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.